The Natalee trial evaluated the use of 3 years of adjuvant ribociclib in combination with an aromatase inhibitor in patients with stage 2 or stage 3 hormone receptor-positive, HER2-negative breast cancer and found that the addition of ribociclib significantly improved disease-free survival (DFS) [76]. The gene discussed is NR4A1; the disease is breast carcinoma.